Universal Versus Platelet Reactivity Assay-Driven Use of P2Y12 Inhibitors in Acute Coronary Syndrome Patients: A Cost-Effectiveness Analysis From a United Kingdom Perspective

被引：0
|
作者：
Coleman, Craig I. [1 ]
Limone, Brendan L. [1 ]
机构：
[1] Univ Connecticut, Sch Pharm, Hartford, CT 06112 USA
来源：
CIRCULATION | 2013年 / 128卷 / 22期
关键词：
Antiplatelet drugs; Acute coronary syndromes; Evidence-based medicine; Cost-effectiveness; Health economics;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
12934
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients Cost-effectiveness analyses for six European perspectives
    Coleman, Craig I.
    Limone, Brendan L.
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (01) : 103 - 110
  • [2] Universal Versus Platelet Reactivity Assay-Driven Use of P2Y12 Inhibitors in Acute Coronary Syndrome Patients: Cost-Effectiveness Analyses from Five European Perspectives
    Coleman, Craig I.
    Limone, Brendan L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B52 - B52
  • [3] Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome
    Coleman, Craig I.
    Limone, Brendan L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2013, 112 (03): : 355 - 362
  • [4] COST-EFFECTIVENESS OF UNIVERSAL VERSUS ASSAY-DRIVEN ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROME PATIENTS
    Coleman, C., I
    Limone, B. L.
    VALUE IN HEALTH, 2013, 16 (03) : A284 - A284
  • [5] Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome
    Kim, Kibum
    Touchette, Daniel R.
    Cavallari, Larisa H.
    Ardati, Amer K.
    DiDomenico, Robert J.
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (05) : 533 - 546
  • [6] Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome
    Kibum Kim
    Daniel R. Touchette
    Larisa H. Cavallari
    Amer K. Ardati
    Robert J. DiDomenico
    Cardiovascular Drugs and Therapy, 2019, 33 : 533 - 546
  • [7] Evaluation of cost-effectiveness of platelet reactivity analysis using the VerifyNow P2Y(12) assay in patients after acute coronary syndrome
    Rudakova, A. V.
    Lomakin, N. V.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2015, 11 (04) : 359 - 364
  • [8] EXAMINING THE COST-EFFECTIVENESS OF EMPIRICAL PASSIVE PERSONALIZATION WITH P2Y12 INHIBITORS IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Suh, Kangho
    Basu, Anirban
    Branch, Kelley
    Carlson, Josh
    MEDICAL DECISION MAKING, 2020, 40 (01) : E74 - E75
  • [9] Novel Platelet ADP P2Y12 Inhibitors in the Treatment of Acute Coronary Syndrome
    Tan, Guang-Ming
    Lam, Yat-Yin
    Yan, Bryan P.
    CARDIOVASCULAR THERAPEUTICS, 2012, 30 (04) : e167 - e173
  • [10] Efficacy and safety of newer P2Y12 inhibitors versus clopidogrel in patients with acute coronary syndrome
    Fei, Y.
    Lam, C.
    Cheung, B.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1631 - 1631
12345